Latin America urged to treat health spending as investment, FIFARMA report says

Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA.

The industry group has published Analysis of Health Budget Practices in eight Latin American Countries, a report funded by FIFARMA and prepared by Duke University’s Global Health Innovation Center. It examines health budget planning, allocation and execution in Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico and Peru.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical